Chapter 36: Drug Development

Drug Development explains the quantitative assessment of drug potency using metrics such as the effective concentration (EC50) and inhibitory concentration (IC50), while noting the necessity of minimizing side effects by achieving a favorable therapeutic index. A significant portion of the chapter focuses on the pharmacokinetic hurdles summarized by the acronym ADME (Absorption, Distribution, Metabolism, and Excretion). This section details the factors influencing oral bioavailability, including Lipinski's rules regarding molecular weight and hydrophobicity, and describes the metabolic biotransformations that occur primarily in the liver. These metabolic processes are categorized into Phase I oxidation reactions, often catalyzed by the cytochrome P450 enzyme family, and Phase II conjugation reactions that increase water solubility for excretion via the kidneys or bile. The narrative also examines the diverse origins of pharmaceutical agents, ranging from serendipitous discoveries like penicillin and sildenafil to the systematic screening of natural product libraries which yielded aspirin and statins. Advanced techniques in medicinal chemistry are highlighted, including combinatorial chemistry, split-pool synthesis, and structure-based drug design, illustrated by the development of HIV protease inhibitors and COX-2 selective anti-inflammatory drugs. Furthermore, the chapter discusses the transformative role of genomics and pharmacogenetics in identifying new protein targets and tailoring treatments to individual genetic profiles. The discussion concludes with an outline of the regulatory landscape, detailing the phases of clinical trials from initial safety testing to post-market surveillance, and addresses the evolutionary challenge of drug resistance in cancer and infectious pathogens, such as the emergence of beta-lactamases and multidrug resistance transporters.